$EMCURE

* CDSCO Approval: Emcure Pharma can expand the use of Poviztra® (semaglutide) in India for treating adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (F2–F3). * First-in-Class Opportunity: Innovator semaglutide becomes the first and only GLP-1 receptor agonist approved in India for this MASH indication, addressing a progressive liver disease with limited treatment options. * Positive for Emcure: The expanded indication broadens Poviztra’s addressable market beyond weight management, potentially strengthening Emcure’s presence in the fast-growing metabolic and cardiometabolic therapy segment.